Literature DB >> 16788097

Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation.

Vanessa Rowe1, Tatjana Banovic, Kelli P MacDonald, Rachel Kuns, Alistair L Don, Edward S Morris, Angela C Burman, Helen M Bofinger, Andrew D Clouston, Geoffrey R Hill.   

Abstract

Host antigen-presenting cells (APCs) are known to be critical for the induction of graft-versus-host disease (GVHD) after allogeneic bone marrow transplantation (BMT), but the relative contribution of specific APC subsets remains unclear. We have studied the role of host B cells in GVHD by using B-cell-deficient microMT mice as BMT recipients in a model of CD4-dependent GVHD to major histocompatibility complex antigens. We demonstrate that acute GVHD is initially augmented in microMT recipients relative to wild-type recipients (mortality: 85% vs 44%, P < .01), and this is the result of an increase in donor T-cell proliferation, expansion, and inflammatory cytokine production early after BMT. Recipient B cells were depleted 28-fold at the time of BMT by total body irradiation (TBI) administered 24 hours earlier, and we demonstrate that TBI rapidly induces sustained interleukin-10 (IL-10) generation from B cells but not dendritic cells (DCs) or other cellular populations within the spleen. Finally, recipient mice in which B cells are unable to produce IL-10 due to homologous gene deletion develop more severe acute GVHD than recipient mice in which B cells are wild type. Thus, the induction of IL-10 in host B cells during conditioning attenuates experimental acute GVHD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16788097     DOI: 10.1182/blood-2006-04-016063

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  43 in total

1.  Recipient B cells are not required for graft-versus-host disease induction.

Authors:  Catherine Matte-Martone; Xiajian Wang; Britt Anderson; Dhanpat Jain; Anthony J Demetris; Jennifer McNiff; Mark J Shlomchik; Warren D Shlomchik
Journal:  Biol Blood Marrow Transplant       Date:  2010-03-23       Impact factor: 5.742

2.  Regulatory B cells promote graft-versus-host disease prevention and maintain graft-versus-leukemia activity following allogeneic bone marrow transplantation.

Authors:  Yue Hu; Gan-Lin He; Xiang-Yu Zhao; Xiao-Su Zhao; Yu Wang; Lan-Ping Xu; Xiao-Hui Zhang; Xue-Zhong Yu; Kai-Yan Liu; Ying-Jun Chang; Xiao-Jun Huang
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

3.  Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation.

Authors:  Isao Tawara; Motoko Koyama; Chen Liu; Tomomi Toubai; Dafydd Thomas; Rebecca Evers; Peter Chockley; Evelyn Nieves; Yaping Sun; Kathleen P Lowler; Chelsea Malter; Norihiro Nishimoto; Geoffrey R Hill; Pavan Reddy
Journal:  Clin Cancer Res       Date:  2010-11-03       Impact factor: 12.531

4.  Flagellin, a TLR5 agonist, reduces graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients while enhancing antiviral immunity.

Authors:  Mohammad S Hossain; David L Jaye; Brian P Pollack; Alton B Farris; Malefa L Tselanyane; Ebenezer David; John D Roback; Andrew T Gewirtz; Edmund K Waller
Journal:  J Immunol       Date:  2011-10-17       Impact factor: 5.422

Review 5.  Biology of graft-versus-host responses: recent insights.

Authors:  Kelli P MacDonald; Warren D Shlomchik; Pavan Reddy
Journal:  Biol Blood Marrow Transplant       Date:  2013-01       Impact factor: 5.742

Review 6.  Cytokine mediators of chronic graft-versus-host disease.

Authors:  Kelli Pa MacDonald; Bruce R Blazar; Geoffrey R Hill
Journal:  J Clin Invest       Date:  2017-06-30       Impact factor: 14.808

7.  Donor- but not host-derived interleukin-10 contributes to the regulation of experimental graft-versus-host disease.

Authors:  Isao Tawara; Yaping Sun; Chen Liu; Tomomi Toubai; Evelyn Nieves; Rebecca Evers; Mariem Alrubaie; Nathan Mathewson; Hiroya Tamaki; Pavan Reddy
Journal:  J Leukoc Biol       Date:  2012-01-18       Impact factor: 4.962

8.  Alloreactive CD8 T cell tolerance requires recipient B cells, dendritic cells, and MHC class II.

Authors:  Thomas Fehr; Fabienne Haspot; Joshua Mollov; Meredith Chittenden; Timothy Hogan; Megan Sykes
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

9.  MHC Class II Antigen Presentation by the Intestinal Epithelium Initiates Graft-versus-Host Disease and Is Influenced by the Microbiota.

Authors:  Motoko Koyama; Pamela Mukhopadhyay; Iona S Schuster; Andrea S Henden; Jan Hülsdünker; Antiopi Varelias; Marie Vetizou; Rachel D Kuns; Renee J Robb; Ping Zhang; Bruce R Blazar; Ranjeny Thomas; Jakob Begun; Nicola Waddell; Giorgio Trinchieri; Robert Zeiser; Andrew D Clouston; Mariapia A Degli-Esposti; Geoffrey R Hill
Journal:  Immunity       Date:  2019-09-18       Impact factor: 31.745

Review 10.  Chronic graft-versus-host disease: biological insights from preclinical and clinical studies.

Authors:  Kelli P A MacDonald; Geoffrey R Hill; Bruce R Blazar
Journal:  Blood       Date:  2016-11-07       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.